Shots:
- Turbine has entered into a research collaboration with Merck to simulate hard-to-treat cancer pts populations that are challenging to study in traditional lab settings
- As per the deal, Meck will leverage Turbine’s Simulated Cells to develop virtual tumor models that mimic hard-to-study, treatment-resistant subtypes to validate novel targets, biomarkers, & combination therapies
- Collaboration includes a 1yr. term with an option for Merck to extend multi-year access to Turbine’s virtual lab & tumor models
Ref: PRNewsWire | Image: Turbine & Merck | Press Release
Related News:- Sanofi Enters a ~$395M Asset Purchase Agreement with Visirna Therapeutics (Arrowhead) for Plozasiran in Greater China
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
